Has Clemens Bergwitz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,509 in general payments to Clemens Bergwitz, MD across 28 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Clemens Bergwitz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Clemens Bergwitz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Clemens Bergwitz, MD

Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1518957067

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 63.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $14,849 and has fallen 67.4% since, to $4,837 in 2025.

$30,509in general payments, 2019–2025

Across 28 payments — averaging $1089.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pharmacosmos Therapeutics Inc.$19K
AstraZeneca$6K
Biomarin Pharmaceutical Inc.$3K
Kyowa Kirin, Inc.$2K
Amgen$14
Ultragenyx Pharmaceutical Inc.$14

$704,944in research payments, 2019–2025

Across 34 payments — averaging $20,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Kyowa Kirin, Inc.$620K
Sanofi$85K

What the payments were for

Consulting fees$10,93436%
Speaking & faculty fees$7,34024%
Travel & lodging$11,22337%
Food & beverage$9983%
Education$140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pharmacosmos Therapeutics Inc.	11	$19,261
AstraZeneca	8	$6,164
Biomarin Pharmaceutical Inc.	3	$2,854
Kyowa Kirin, Inc.	4	$2,203
Amgen	1	$14
Ultragenyx Pharmaceutical Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,509 in reported general payments places this provider in the 85th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024

$50,179

Medicare patients

861

Services billed

1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Teriparatide	33	$108,808
TymlosAbaloparatide	27	$69,521
ForteoTeriparatide	13	$50,176
Cinacalcet Hcl	36	$9,650
Alendronate Sodium	413	$4,439
SynthroidLevothyroxine Sodium	40	$3,021
Levothyroxine Sodium	258	$2,228
Risedronate Sodium	57	$1,428
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic	34	$1,298
Calcitriol	43	$1,092
Allopurinol	13	$818
Raloxifene Hcl	23	$416
Ibandronate Sodium	16	$354
Hydrochlorothiazide	41	$180
Chlorthalidone	20	$70

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in New Haven

Ania JastreboffNew Haven$536K
Silvio InzucchiNew Haven$461K
Philip GoldbergNew Haven$324K
Kevan HeroldNew Haven$261K
Gerald ShulmanNew Haven$194K
Karl InsognaNew Haven$68K
Richard KibbeyNew Haven$18K
Peter TebbenNew Haven$17K
Surani FernandoNew Haven$13K
Irina RosewaterNew Haven$12K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →